EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: A meta-analysis

Cancer Investigation

Volumn 29, Issue 9, 2011, Pages 626-634

  Han, Chengbo ^a   Ma, Jietao ^a   Zhao, Jianzhu ^a   Zhou, Yang ^a   Jing, Wei ^a   Zou, Huawei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; KRAS; Metastasis; Mutation; Nonsmall cell lung cancer; Primary tumor

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ARTICLE; CARCINOGENESIS; COPY NUMBER VARIATION; GENE AMPLIFICATION; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; METASTASIS; MUTATION RATE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CARCINOMA, NON-SMALL-CELL LUNG; GENE AMPLIFICATION; GENES, RAS; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80054864824     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.621914     Document Type: Article

References (45)

1. Jemal A, Siegel R,Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009;59(4):225-249.
2. Marsit CJ, Hasegawa M, Hirao T, Kim DH, Aldape K, Hinds PW, Wiencke JK, Nelson HH, Kelsey KT. Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in nonsmall-cell lung cancer. Cancer Res 2004;64(23):8702-8707. (Pubitemid 39552086)
3. Garnis C, Lockwood WW, Vucic E, Ge Y, Girard L, Minna JD, Gazdar AF, Lam S, MacAulay C, Lam WL. High resolution analysis of nonsmall cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 2006;118(6):1556-1564.
4. Mounawar M, Mukeria A, Le Calvez F, Hung RJ, Renard H, Cortot A, Bollart C, Zaridze D, Brennan P, Boffetta P, Brambilla E, Hainaut P. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 2007;67(12):5667-5672. (Pubitemid 46984998)
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-957.
6. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY,Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372(9652):1809-1818.
7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-957.
8. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y,Okinaga S, Hirano H, Yoshimori K,Harada T,Ogura T, Ando M,Miyazawa H, Tanaka T, Saijo Y,Hagiwara K,Morita S,Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362(25):2380- 2388.
9. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA Jr, FranklinWA, Crowley J,Gandara DR. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23(28):6838-6845.
10. Dacic S, Flanagan M, Cieply K, Ramalingam S, Luketich J, Belani C, Yousem SA. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol 2006;125(6):860-865. (Pubitemid 43801536)
11. Dziadziuszko R,Witta SE, Cappuzzo F, Park S, Tanaka K, Danenberg PV, Baron AE, Crino L, Franklin WA, Bunn PA Jr, Varella- Garcia M, Danenberg KD, Hirsch FR. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in nonsmall cell lung cancer. Clin Cancer Res 2006;12(10):3078-3084. (Pubitemid 43837354)
12. Pirker R, Pereira JR, Szczesna A, von Pawel J,Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009;373(9674):1525-1531.
13. Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/ carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(6):918-927.
14. Riely GJ,Marks J, PaoW. KRAS mutations in non-small cell lung cancer. Proc AmThorac Soc 2009;6(2):201-205.
15. UramotoH,Mitsudomi T.Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 2007;96(6):857-863. (Pubitemid 46452294)
16. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13(10):2890-2896. (Pubitemid 46849563)
17. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S. Assessment of somatic k-RASmutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9(10):962-972.
18. Paez JG, JännePA, Lee JC, Tracy S,GreulichH,Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, EckMJ, Sellers WR, Johnson BE,Meyerson M. EGFRmutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-1500. (Pubitemid 38720929)
19. Spremulli EN, Dexter DL. Human tumor cell heterogeneity and metastasis. J Clin Oncol 1983;1(8):496-509. (Pubitemid 13020050)
20. Daniele L, Cassoni P, Bacillo E, Cappia S, Righi L,VolanteM, Tondat F, Inghirami G, Sapino A, Scagliotti GV, Papotti M, Novello S. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol 2009;4(6):684-688.
21. Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, Sabatier L, Dartevelle P, Taranchon E, Besse B, Validire P, Italiano A, Soria JC. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. JThorac Oncol 2009;4(10):1212-1220.
22. Cortot AB, Italiano A, Burel-Vandenbos F, Martel-Planche G, Hainaut P. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer 2010;116(11):2682-2687.
23. Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, Yu CJ, Yang CH, Lee YC, Yang PC, Shih JY. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-smallcell lung cancer. Ann Oncol 2009;20(4):696-702.
24. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, Mavroudis D, Voutsina A. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008;99(6):923-929.
25. Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, Shimizu E, Yokota J. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 2006;119(6):1491-1494. (Pubitemid 44258830)
26. Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Jänne PA, Ahn MJ. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 2009;4(7):809-815.
27. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009;15(14):4554-4560.
28. Badalian G, Barbai T, Rásó E, Derecskei K, Szendroi M, T́imár J. Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status. Pathol Oncol Res 2007;13(2):99-104. (Pubitemid 47204731)
29. Monaco SE, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, Dacic S. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol 2010;41(1):94-102.
30. Italiano A, Vandenbos FB, Otto J, Mouroux J, Fontaine D, Marcy PY, CardotN,ThyssA, PedeutourF.Comparisonof the epidermal growth factor receptor gene and protein in primary non-smallcell- lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol 2006;17(6):981-985. (Pubitemid 43778990)
31. Rao C, Hu Q, Ma J, Li J, Zhang C, Shen L, Wei Q. Comparison of the epidermal growth factor receptor protein expression between primary non-small cell lung cancer and paired lymph nodemetastases: implications for targeted nuclide radiotherapy. J Exp Clin Cancer Res 2010;29:1-7.
32. Watzka SB, Rauscher-Pötsch I, Nierlich P, Setinek U, Köstler WJ, Pötschger U,Müller MR, Attems J. Concordance between epidermal growth factor receptor status in primary non-small-cell lung cancer and metastases: a post-mortem study. Eur J Cardiothorac Surg 2010;38(1):34-37.
33. Bozzetti C, Tiseo M, Lagrasta C, Nizzoli R, Guazzi A, Leonardi F, Gasparro D, Spiritelli E, RuscaM, Carbognani P,MajoriM, Franciosi V, Rindi G, Ardizzoni A. Comparison between epidermal growth factor receptor (EGFR) gene expression in primary nonsmall cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites. J Thorac Oncol 2008;3(1):18-22.
34. Li S, Rosell R, Urban A, Font A, Ariza A, Armengol P, Abad A, Navas JJ, Monzo M. K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma. Lung Cancer 1994;11:19-27. (Pubitemid 24244392)
35. Gallegos Ruiz MI, van Cruijsen H, Smit EF, Grünberg K, Meijer GA, Rodriguez JA, Ylstra B, Giaccone G. Genetic heterogeneity in patients with multiple neoplastic lung lesions: a report of three cases. JThorac Oncol 2007;2(1):12-21. (Pubitemid 47163923)
36. Rao UN, Jones MW, Finkelstein SD. Genotypic analysis of primary and metastatic cutaneous melanoma. Cancer Genet Cytogenet 2003;140:37-44. (Pubitemid 36110637)
37. Takahashi K, Kohno T, Matsumoto S, Nakanishi Y, Arai Y, Fujiwara T, Tanaka N, Yokota J. Clonality and heterogeneity of pulmonary blastoma from the viewpoint of genetic alterations: a case report. Lung Cancer 2007;57(1):103-108. (Pubitemid 46843334)
38. Kuukasjärvi T, Karhu R, Tanner M, Kähkönen M, Schäffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997;57(8):1597-1604. (Pubitemid 27175581)
39. Tórtola S, Steinert R, Hantschick M, Peinado MA, Gastinger I, Stosiek P, Lippert H, Schlegel W, Reymond MA. Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol 2001;19(11):2837-2843. (Pubitemid 32538192)
40. Racila E, Euhus D,Weiss AJ, Rao C,McConnell J, Terstappen LW, Uhr JW. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 1998;95(8):4589-4594. (Pubitemid 28207957)
41. Hayes DF,Walker TM, Singh B, Vitetta ES, Uhr JW, Gross S, Rao C,DoyleGV, Terstappen LW.Monitoring expression ofHER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002;21(5):1111-1117.
42. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in nonsmall- cell lung cancer. J Natl Cancer Inst 2005;97(9):643-655. (Pubitemid 40812628)
43. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S,Nokihara H, Yamamoto N, Sekine I, KunitohH, Shibata T, Sakiyama T, Yoshida T, Tamura T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-6837.
44. Pinter F, Papay J, Almasi A, Sapi Z, Szabo E, Kanya M, Tamasi A, Jori B, Varkondi E, Moldvay J, Szondy K, Keri G, Dominici M, Conte P, Eckhardt S, Kopper L, Schwab R, Petak I. Epidermal growth factor receptor (EGFR) high gene copy number and activatingmutations in lung adenocarcinomas are not consistently ccompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn 2008;10:160-168. (Pubitemid 351428398)
45. Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, Jeon HS, Cho S, Lee EB, Cha SI, Park TI, Kim CH, Jung TH, Park JY. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010;5(11):1734-1740.